Healthy subjects aged 18-64 years ( n = 1240 ) and 65 years ( n = 1352 ) were vaccinated with 1 of 8 investigational vaccine formulations varying in antigen quantity ( 3.75 g to 30 g of hemagglutinin ) and MF59 ( ) adjuvant ( none , half dose , or full dose ) .